A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a pioneering diagnostics technology company. Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. We do this primarily by developing molecular diagnostic test kits that empower our customers to run their own tests to participate in the patient-care value chain, which is counter-positioned with the central laboratory model. Our decentralized approach also puts testing in the hands of researchers to enable more studies, which inspires innovation, which we believe can improve standards of care while also creating demand for more testing. We develop tests that measure both established biomarkers as well as pioneer the adoption of new and more effective biomarkers. We believe that combining innovative science with a simple, but disruptive, business model can create enormous value.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.4M | - | - | - | - | - |
| Net Income | -61M | -61M | -29M | -73M | -22M | -16M |
| EPS | $-3.21 | $-4.66 | $-3.75 | $-13.25 | $-8.80 | $-8.40 |
| Free Cash Flow | -24M | -21M | -24M | -50M | -21M | -12M |
| ROIC | -110.2% | -137.5% | -97.0% | -41.5% | -68.5% | -126.2% |
| Gross Margin | 54.5% | - | - | - | - | - |
| Debt/Equity | 0.00 | -3.86 | 2.41 | 1.76 | 0.06 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -61M | -61M | -25M | -18M | -22M | -15M |
| Operating Margin | -1392.9% | - | - | - | - | - |
| ROE | 0.0% | -1487.1% | -140.3% | -214.1% | -130.9% | -402.6% |
| Shares Outstanding | 29M | 13M | 29M | 6M | 3M | 2M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.4M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 54.5% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -8.7M | -11M | -19M | -15M | -22M | -18M | -25M | -61M | -61M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1392.9% |
| Net Income | -8.7M | -11M | -19M | -16M | -22M | -73M | -29M | -61M | -61M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1380.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 19M | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -83.9% | -60.9% | -145.8% | -126.2% | -68.5% | -41.5% | -97.0% | -137.5% | -110.2% |
| ROE | -83.9% | -110.1% | -440.0% | -402.6% | -130.9% | -214.1% | -140.3% | -1487.1% | 0.0% |
| ROA | -68.6% | -82.2% | -189.7% | -159.7% | -90.8% | -73.4% | -38.4% | -110.8% | -138.3% |
| Cash Flow | |||||||||
| Op. Cash Flow | -4.2M | -7.5M | -13M | -12M | -20M | -46M | -23M | -21M | -22M |
| Free Cash Flow | -4.7M | -7.6M | -13M | -12M | -21M | -50M | -24M | -21M | -24M |
| Owner Earnings | -6.1M | -8.6M | -15M | -14M | -23M | -57M | -28M | -24M | -25M |
| CapEx | 500K | 106K | 91K | 31K | 918K | 4.3M | 281K | 516K | 1.9M |
| Maint. CapEx | 41K | 145K | 338K | 438K | 344K | 1.5M | 1.6M | 1.5M | 1.5M |
| Growth CapEx | 459K | 0 | 0 | 0 | 574K | 2.8M | 0 | 0 | 444K |
| D&A | 41K | 145K | 338K | 438K | 344K | 1.5M | 1.6M | 1.5M | 1.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.8M | 922K | 1.6M | 1.5M | 3.0M | 10M | 2.8M | 1.8M | 1.8M |
| Debt Repayment | 0 | 0 | 133K | 800K | 667K | 1.3M | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | -8.0M | -9.9M | -6.5M | -7.7M | -20M | N/A | N/A | N/A | -19M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 19M |
| Long-Term Debt | 0 | 310K | 1.1M | 347K | 1.9M | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.00 | 0.03 | 0.24 | 0.10 | 0.06 | 1.76 | 2.41 | -3.86 | 0.00 |
| Interest Coverage | N/A | N/A | -145.0 | -107.1 | -145.4 | -749.9 | -3590.9 | -1453.4 | -1453.4 |
| Equity | 10M | 9.9M | 4.4M | 3.4M | 31M | 34M | 20M | -12M | -9.2M |
| Total Assets | 13M | 14M | 10M | 9.5M | 40M | 100M | 75M | 35M | 44M |
| Total Liabilities | 2.3M | 4.6M | 5.8M | 6.1M | 9.0M | 60M | 49M | 47M | 53M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 29M | 29M |
| Retained Earnings | -24M | -35M | -55M | -71M | -94M | -261M | -290M | -351M | -351M |
| Working Capital | 8.6M | 8.4M | 4.1M | 3.1M | 19M | 13M | 3.5M | 4.5M | 4.5M |
| Current Assets | 11M | 13M | 8.5M | 8.6M | 23M | 26M | 11M | 12M | 12M |
| Current Liabilities | 2.3M | 4.3M | 4.5M | 5.6M | 4.4M | 12M | 7.2M | 7.3M | 7.3M |
| Per Share Data | |||||||||
| EPS | -8.40 | -8.40 | -12.80 | -8.40 | -8.80 | -13.25 | -3.75 | -4.66 | -3.21 |
| Owner EPS | -5.85 | -6.46 | -10.14 | -7.23 | -9.05 | -10.31 | -0.97 | -1.83 | -0.88 |
| Book Value | 10.02 | 7.42 | 2.91 | 1.83 | 12.10 | 6.19 | 0.72 | -0.94 | -0.32 |
| Cash Flow/Share | -4.07 | -5.66 | -8.84 | -6.21 | -7.74 | -8.22 | -0.82 | -1.58 | -2.07 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.0M | 1.3M | 1.5M | 1.9M | 2.5M | 5.5M | 28.6M | 13.1M | 28.7M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 12.5 | 19.4 | 32.7 | 16.1 | 3.5 | 1.0 | 3.5 | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 23.5 |
| FCF Yield | -3.6% | -4.0% | -9.4% | -21.2% | -19.1% | -150.1% | -33.0% | -77.0% | -23.1% |
| Market Cap | 130M | 191M | 144M | 55M | 108M | 33M | 71M | 28M | 103M |
| Avg. Price | 125.00 | 93.26 | 112.08 | 51.04 | 55.41 | 21.16 | 4.83 | 2.92 | 3.61 |
| Year-End Price | 125.00 | 144.00 | 95.00 | 29.40 | 42.40 | 6.00 | 2.50 | 2.11 | 3.61 |
Insight Molecular Diagnostics Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Insight Molecular Diagnostics Inc. (IMDX) has a 5-year average return on invested capital (ROIC) of -94.1%. This is below average and may indicate limited pricing power.
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $103M. It is classified as a small-cap stock.
Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a regular dividend.
Insight Molecular Diagnostics Inc. (IMDX) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Insight Molecular Diagnostics Inc. (IMDX) generated $-21 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Insight Molecular Diagnostics Inc. (IMDX) reported earnings per share (EPS) of $-4.66 in its most recent fiscal year.
Insight Molecular Diagnostics Inc. (IMDX) has a return on equity (ROE) of -1487.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Insight Molecular Diagnostics Inc. (IMDX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Insight Molecular Diagnostics Inc. (IMDX) has a book value per share of $-0.94, based on its most recent annual SEC filing.